132 South 10th Street
Main Building, Suite 480
Philadelphia, PA 19107
(215) 955-8900
(215) 503-2578 fax
Main Building, Suite 480
Philadelphia, PA 19107
(215) 955-8900
(215) 503-2578 fax
Most Recent Peer-reviewed Publications
- Refractory pancolitis: A novel presentation of idiopathic myointimal hyperplasia of mesenteric veins
- Pulmonary capillaritis: A rare extra-intestinal manifestation of inflammatory bowel disease
- Efficacy of morning-only compared with split-dose polyethylene glycol electrolyte solution for afternoon colonoscopy: A randomized controlled single-blind study
- Rectal Perforation by Retroflexion of the Colonoscope Managed by Endoclip Closure
- An Unusual Cause of Hematemesis
- A validation study of 3 grading systems to evaluate small-bowel cleansing for wireless capsule endoscopy: a quantitative index, a qualitative evaluation, and an overall adequacy assessment
- Complete resolution of gastric amyloidosis after autologous stem cell transplantation.
- Is single-cell apoptosis sufficient for the diagnosis of graft-versus-host disease in the colon?
- Providing an endoscopy report to patients after a procedure: a low-cost intervention with high returns
- Adenocarcinoma of the prostate presenting as an obstructing rectal mass
- Capsule endoscopy diagnosis of radiation enteritis in a patient previously considered to have celiac sprue.
- Tolerability and patient acceptance of sodium phosphate tablets compared with 4-L PEG solution in colon cleansing: Combined results of 2 identically designed, randomized, controlled, parallel group, multicenter phase 3 trials
- A novel PEG 3350 formulation
- Quantity of sodium and phosphate in Visicol® tablet and Fleet® Phospho-soda® liquid bowel preparations [2] (multiple letters)
- Safety of sodium phosphate tablets in patients receiving propofol-based sedation for colonoscopy.
- Safety of sodium phosphate for colonoscopy [1] (multiple letters)
- Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: Two identically designed, randomized, controlled, parallel group, multicenter phase III trials
- Nafcillin-associated jaundice [1]
- Cholestatic hepatitis associated with the use of nafcillin